Tag Archives: R&D

Chairman Bernanke’s Speach on Government R&D Spending Policy and Economic Development

FED Chairman Ben Bernanke spoke about government funding of research and development at Georgetown University for the “New Building Blocks for Jobs and Economic Growth” conference. Highlights relating to Intellectual Property: 1.  “Economic policy affects innovation and long-run economic growth in many ways. A stable macroeconomic environment; sound public finances; and well-functioning financial, labor, and product markets all support innovation, entrepreneurship, and growth, as do effective tax, trade, and regulatory policies. Policies directed at objectives such as the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Therapeutic Discovery Project Awards Provide Much Needed R&D Support

This morning, U.S. Treasury Secretary Timothy Geithner and HHS Secretary Kathleen Sebelius announced the awardees of the Therapeutic Discovery Project (TDP). We are running a few analytics on the recipient list and posting them here, along with links to relevant articles/blogs. Here is a primer: 5600 projects were submitted by ~3000 companies The maximum amount a project received was $244,479 78% of projects received the maximum amount Average project award was $217,108 72% of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Press Release: BIO and AUTM file Amicus Brief in Myriad Case

The Biotechnology Industry Organization (BIO) filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on Friday, October 29th, in an appeal of a lawsuit brought by the American Civil Liberties Union on behalf of a number of plaintiffs against Myriad Genetics, the U.S. Patent and Trademark Office, and others. The brief, filed jointly with the Association of University Technology Managers (AUTM), supports the patentability of isolated DNA molecules, noting that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

1Q Cash Spending – Small Biotechs Still Spending Less

A comparison of cash spent on operations in the 1st quarter of 2010 vs the 1st quarters of 2009 and 2008 for small public biotechs shows a slowing in the precipitous drop seen over the last 2 years. However, the average small biotech is still spending less cash vs. 2008. When compared to 1Q08, the median cash flow from operations (CFO) in 1Q10 is down -40%. From 1Q09, median CFO is down -15%. See chart Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,